Revolo Biotherapeutics Announces Positive Topline Data from Phase 2a Trial of ‘1104 in Adults with Active Eosinophilic Esophagitis
April 19, 2023Business Services
NEW ORLEANS and CAMBRIDGE, UK, April 19 2023 – Revolo Biotherapeutics (“Revolo” or the “Company”), a company developing therapies that …
Engimmune Therapeutics appoints Dr. Lars Nieba as Chief Executive Officer
April 19, 2023Business Services
Basel, Switzerland, April 19, 2023. Engimmune Therapeutics AG (“Engimmune”), a Swiss biotech company developing novel T-cell receptor (TCR)-based therapeutics, today …
Oxford BioTherapeutics announces Phase 1b trial in collaboration with GORTEC to investigate OBT076 in Adenoid Cystic Carcinoma (ACC) of the head and neck
April 19, 2023Business Services
Oxford, UK and San Jose, Calif., 19 April 2023 – Oxford BioTherapeutics Ltd.
Acadia Pharmaceuticals announces commercialisation of Daybue for Rett syndrome
April 19, 2023Sales and Marketing
Acadia Pharmaceuticals has announced that Daybue (trofinetide) is now available for adult and paediatric patients over the age of two …
ANGLE and BioView partner to develop a CTC-based HER2 assay
April 19, 2023Medical Communications
ANGLE, a liquid biopsy company, and BioView, a company developing, manufacturing and marketing automated microscopy imaging and analysis solutions, have …
FDA issues update around changes to COVID-19 vaccines’ EUAs
April 19, 2023Medical Communications
The FDA has announced its amendment of the emergency use authorisations (EUAs) for the Moderna and Pfizer-BioNTech COVID-19 bivalent mRNA …
Neuspera Medical receives FDA approval for peripheral nerve pain system
April 19, 2023Medical Communications
Medical device company Neuspera Medical has announced that it has received FDA approval for its implantable system, used to treat …
OWEN MUMFORD WINS DISTINCTION IN RED DOT AWARD (PRODUCT DESIGN 2023) FOR AIDAPTUS® AUTO-INJECTOR
April 18, 2023Business Services
OXFORD, England, 18 April 2023 – Owen Mumford is proud to have been awarded a distinction in the prestigious Red …
Pneumagen further strengthens IP protection for lead product Neumifil with granting of US composition of matter patent
April 18, 2023Business Services
St Andrews, UK – 18 April 2023 – Pneumagen, a clinical stage biotech company developing Neumifil, a broad-spectrum antiviral, intranasal …
NeoPhore signs research collaboration with The Institute of Cancer Research, London
April 18, 2023Business Services
London, UK, 18 April 2023, – NeoPhore Limited, a small molecule neoantigen immuno-oncology company, today announces that it has signed a …
New Data Showing that Transgene and NEC’s Individualized Cancer Vaccine TG4050 Induces Strong and Specific Immune Responses against Tumors Presented at AACR 2023
April 18, 2023Business Services
Strasbourg, France & Tokyo, Japan, April 18, 2023, 9:00 a.m. CET/4:00 p.m. JST – Transgene (Euronext Paris: TNG), a biotech company …
Nouscom Presents New Positive Translational Phase 1b Data of NOUS-PEV, a Personalized Neoantigen Cancer Immunotherapy, in a Late-Breaking Abstract at AACR 2023
April 18, 2023Business Services
BASEL, Switzerland – 18th April 2023 – Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized viral vector immunotherapies, …
MED3000, Eroxon® UK Launch
April 18, 2023Business Services
Futura Medical plc (AIM: FUM) (“Futura” or the “Company”), a pharmaceutical company developing a portfolio of innovative products based on …
Scancell to present ModiFY Phase 1/2 cancer vaccine clinical trial protocol and early efficacy data at the American Association for Cancer Research Annual Meeting
April 18, 2023Business Services
Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer and infectious disease, announces it …
GSK enters into £1.6bn deal to acquire Bellus Health
April 18, 2023Medical Communications
UK-based GSK has announced its plans to acquire Bellus Health, a Canadian late-stage biopharmaceutical company which focuses on treatments for …
Ariceum Therapeutics announces extension of Series A financing for radiopharmaceutical clinical pipeline
April 18, 2023Sales and Marketing
Private biotech company Ariceum Therapeutics has announced the successful completion of Series A extension financing, raising an additional €22.75m following …
Gamida Cell’s Omisirge receives FDA approval
April 18, 2023Research and Development
Cell therapy pioneer Gamida Cell has announced FDA approval of its allogeneic cell therapy, Omisirge (omidubicel-onlv), for use in adult …
FDA approves expanded indication for AbbVie’s chronic migraine treatment
April 18, 2023Medical Communications
US-based AbbVie has announced that the FDA has granted approval for the expanded indication of its preventative chronic migraine treatment …
HUTCHMED Announces NDA Acceptance in China for Fruquintinib in Second-Line Gastric Cancer
April 18, 2023Business Services
Hong Kong, Shanghai & Florham Park, NJ — Tuesday, April 18, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces …
We need more “trial” and less error – a concerted effort is required to include more people aged over 60 in clinical trials, argues longevity experts
April 18, 2023Business Services
The Trial and error report, published today, urges regulators, pharmaceutical companies and researchers to prioritise age diversity at all stages …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
